You are here

Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

Last updated on November 14, 2019

FOR MORE INFORMATION
Study Location
Investigational Site
Phoenix, Arizona, 85050 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Onychomycosis of Toenails
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Clinical diagnosis of distal subungual onychomycosis affecting at least one great
toenail

- KOH positive at screening

- Willingness not to use any other products including nail polish applied to the
toenails during the study

- Women of childbearing potential who are currently sexually active must agree to use
contraception for the entire study period

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Concurrent or recent use of certain topical or systemic medications without a
sufficient washout period

- History of any significant chronic fungal disease other than onychomycosis

- Significant confounding conditions as assessed by study doctor

- Participated in any other trial of an investigational drug or device within 30 days
or participation in a research study concurrent with this study

- Pregnancy or lactation

NCT01302119
Pfizer
Completed
Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
Official Title  ICMJE A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults
Brief SummaryThe purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Onychomycosis of Toenails
Intervention  ICMJE
  • Drug: AN2690 Topical Solution, 5%
    AN2690 Topical Solution, 5%, applied once daily for 48 weeks
  • Drug: Solution Vehicle
    AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Study Arms  ICMJE
  • Experimental: AN2690 Topical Solution, 5%
    AN2690 Topical Solution, 5%
    Intervention: Drug: AN2690 Topical Solution, 5%
  • Placebo Comparator: Solution Vehicle
    Solution Vehicle
    Intervention: Drug: Solution Vehicle
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 4, 2012)
604
Original Estimated Enrollment  ICMJE
 (submitted: February 21, 2011)
600
Actual Study Completion Date  ICMJE February 20, 2013
Actual Primary Completion DateDecember 31, 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Clinical diagnosis of distal subungual onychomycosis affecting at least one great toenail
  • KOH positive at screening
  • Willingness not to use any other products including nail polish applied to the toenails during the study
  • Women of childbearing potential who are currently sexually active must agree to use contraception for the entire study period

Exclusion Criteria:

  • Concurrent or recent use of certain topical or systemic medications without a sufficient washout period
  • History of any significant chronic fungal disease other than onychomycosis
  • Significant confounding conditions as assessed by study doctor
  • Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study
  • Pregnancy or lactation
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01302119
Other Study ID Numbers  ICMJE AN2690-ONYC-302
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:PfizerCT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateMarch 2019

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now